These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L MAbs; 2020; 12(1):1743053. PubMed ID: 32249670 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in silico assessment of the developability of a designed monoclonal antibody library. Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N MAbs; 2019; 11(2):388-400. PubMed ID: 30523762 [TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Antibody Profiler for Computational Developability Assessment. Raybould MIJ; Deane CM Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133 [TBL] [Abstract][Full Text] [Related]
6. Rapid optimization and prototyping for therapeutic antibody-like molecules. Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA MAbs; 2013; 5(2):237-54. PubMed ID: 23392215 [TBL] [Abstract][Full Text] [Related]
7. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment. Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ MAbs; 2022; 14(1):2080628. PubMed ID: 35771588 [TBL] [Abstract][Full Text] [Related]
8. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM MAbs; 2021; 13(1):1980942. PubMed ID: 34850665 [TBL] [Abstract][Full Text] [Related]
9. DOTAD: A Database of Therapeutic Antibody Developability. Li W; Lin H; Huang Z; Xie S; Zhou Y; Gong R; Jiang Q; Xiang C; Huang J Interdiscip Sci; 2024 Sep; 16(3):623-634. PubMed ID: 38530613 [TBL] [Abstract][Full Text] [Related]
10. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling. Park E; Izadi S MAbs; 2024; 16(1):2362788. PubMed ID: 38853585 [No Abstract] [Full Text] [Related]
11. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947 [TBL] [Abstract][Full Text] [Related]
12. Considerations for the Design of Antibody-Based Therapeutics. Goulet DR; Atkins WM J Pharm Sci; 2020 Jan; 109(1):74-103. PubMed ID: 31173761 [TBL] [Abstract][Full Text] [Related]
13. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR MAbs; 2022; 14(1):2020082. PubMed ID: 35104168 [TBL] [Abstract][Full Text] [Related]
14. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB MAbs; 2013; 5(5):646-54. PubMed ID: 23924797 [TBL] [Abstract][Full Text] [Related]
15. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity. Kumar S; Roffi K; Tomar DS; Cirelli D; Luksha N; Meyer D; Mitchell J; Allen MJ; Li L Protein Eng Des Sel; 2018 Jul; 31(7-8):313-325. PubMed ID: 30189027 [TBL] [Abstract][Full Text] [Related]
16. Five computational developability guidelines for therapeutic antibody profiling. Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520 [TBL] [Abstract][Full Text] [Related]
17. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. Lavoisier A; Schlaeppi JM MAbs; 2015; 7(1):77-83. PubMed ID: 25514497 [TBL] [Abstract][Full Text] [Related]
18. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. Geoghegan JC; Fleming R; Damschroder M; Bishop SM; Sathish HA; Esfandiary R MAbs; 2016 Jul; 8(5):941-50. PubMed ID: 27050875 [TBL] [Abstract][Full Text] [Related]
19. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods. Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132 [TBL] [Abstract][Full Text] [Related]
20. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]